) --Welcome to September's Biotech Stock Live Chat. The floor is yours.
It's been a while since I did one of these chats, so a review of the ground rules: I'm here for the next 90 minutes to answer your biotech-investing questions and, hopefully, spark some interactive debate on the hot topics of the day. This chat only works if you participate, so please keep the questions and comments flowing.
If you're at a loss for topics, I have some suggestions that riff off my
announcing the commercial launch of Qsymia on Monday, the weight-loss market share war with
ratchets up a notch.
: NCE status, when? Vascepa launch? Takeout or partnership?
. Which company has the better drug for acute myeloid leukemia?
and its Parkinson's disease drug pimavanserin succeed in the current phase III trial?
garner early FDA approval for their respective cancer drugs?
Let's look ahead to see what's in store for hepatitis C drug stocks like
sign a partner before starting the bavituximab phase III lung cancer study at year's end, as promised?
Let's talk about these stocks today, or any other biotech -investing subject that piques your interest. Please join me live.
--Written by Adam Feuerstein in Boston.
>To contact the writer of this article, click here:
>To follow the writer on Twitter, go to
>To submit a news tip, send an email to:
and become a fan on
Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback;
to send him an email.